Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 09:00 ET | Source: Evaxion

Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate

Evaxion introduces EVX-04, a novel vaccine candidate targeting multiple non-conventional ERV tumor antigens, developed with our AI-Immunology™ platformEVX-04 is a therapeutic cancer vaccine candidate...
October 17, 2025 08:15 ET | Source: Evaxion

Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01

75% Objective Response Rate as 12 out of 16 advanced melanoma patients had objective clinical responses, with 11 of the 12 responders continuing to respond at 24 months follow-upImmune activation...
October 13, 2025 08:00 ET | Source: Evaxion

Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Presentation will cover two-year clinical efficacy, immunogenicity and safety dataData will be presented at an oral session on October 17, 2025, followed by a webinar on October 22, 2025, providing...
May 22, 2025 08:00 ET | Source: Evaxion Biotech

Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01

Generation of additional clinical data allows for a more comprehensive assessment of the full potential of EVX-01, while strengthening the already strong clinical data packageWill provide insights...
April 28, 2025 08:00 ET | Source: Evaxion Biotech

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

80% of EVX-01 vaccine targets triggered a tumor-specific immune response, a substantially higher frequency than what has been reported for other similar vaccine candidatesThe data underscores the...
March 25, 2025 16:30 ET | Source: Evaxion Biotech

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

New biomarker and immune data from the ongoing phase 2 trial with EVX-01 will be presented at the American Association for Cancer Research (AACR) Annual Meeting These data will further add to the...
March 25, 2025 09:56 ET | Source: Research and Markets

Personalized Cancer Vaccine Market & Clinical Trials Outlook 2025: BioNTech, Moderna and myNEO Therapeutics Lead Race in Personalized Cancer Vaccines

Dublin, March 25, 2025 (GLOBE NEWSWIRE) -- The "Personalized Cancer Vaccine Market Opportunity & Clinical Trials Outlook 2025" report has been added to ResearchAndMarkets.com's offering. ...
February 25, 2025 08:00 ET | Source: Evaxion Biotech

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

Originally planned as a two-year study, the trial has been extended by an additional year to collect three-year clinical outcome data The additional third year of EVX-01 dosing may provide further...
August 08, 2024 08:00 ET | Source: Evaxion Biotech

Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September

COPENHAGEN, Denmark, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, is...
June 26, 2024 07:30 ET | Source: Evaxion Biotech

Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method

Positive Feedback Received: An International Preliminary Report on Patentability (IPRP) indicates promising prospects for obtaining granted patents and protecting the inventionUnique Attributes and...